Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design

Title: Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design

Volume: 6 Issue: 2

Author(s): Dinesh Khanna, James R. Seibold, Athol Wells, Oliver Distler, Yannick Allanore, Chris Denton and Daniel E. Furst

Affiliation:

Keywords: Systemic sclerosis, lung, outcome measures

Abstract: Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.

Cite this article as:

Khanna Dinesh, Seibold James R., Wells Athol, Distler Oliver, Allanore Yannick, Denton Chris and E. Furst Daniel, Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design, Current Rheumatology Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339710791330768